Molecular biology and targeted therapy of cutaneous T-cell lymphomas.
Cutaneous T-cell lymphoma (CTCL) is an extra-nodal non-Hodgkin lymphoma of mature T cells. These tumor cells home to and persist in the skin, producing a broad spectrum of clinical entities. Recent results of basic research on tumor biology and tumor immunology as well as molecular genetics of cutaneous T-cell lymphoma have fostered the development of new therapeutic approaches. Several clinical trials testing these targeted therapies have shown encouraging results. This article provides an overview of recent research developments and therapeutic strategies for cutaneous T-cell lymphoma.
Klemke
C D
CD
Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karls-University of Heidelberg, Mannheim, Germany. claus-detlev.klemke@haut.ma.uni-heidelberg.de
Goerdt
S
S
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000945:Antigens, Differentiation, T-Lymphocyte; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis; D000077610:Bexarotene; D014408:Biomarkers, Tumor / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D004167:Diphtheria Toxin / Q000627:therapeutic use; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D015603:Keratinocytes / Q000276:immunology; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D008264:Macrophages / Q000276:immunology; D008407:Mast Cells / Q000276:immunology; D008562:Membrane Glycoproteins / Q000276:immunology; D016328:NF-kappa B / Q000276:immunology; D019707:Receptors, Chemokine / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use; D016896:Treatment Outcome; D000077337:Vorinostat
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000945:Antigens, Differentiation, T-Lymphocyte; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C063419:CTAGE1 protein, human; D016207:Cytokines; D004167:Diphtheria Toxin; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D007376:Interleukin-2; D008562:Membrane Glycoproteins; D016328:NF-kappa B; D019707:Receptors, Chemokine; D011993:Recombinant Fusion Proteins; D013764:Tetrahydronaphthalenes; C078456:denileukin diftitox; D000074323:Alemtuzumab; D000077337:Vorinostat; D000077610:Bexarotene; C520522:zanolimumab